PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2024-01-04

Date Title Company
04-Jan-2024 Aptar Digital Health and Gerresheimer Collaborate to Develop Integrated Solution for Subcutaneous Cancer Therapy Aptar Digital Health
04-Jan-2024 Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide AccessWire
04-Jan-2024 Seraxis' Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes AccessWire
04-Jan-2024 BioInvent Announces 2024 Strategic Priorities and Anticipated Milestones AccessWire
04-Jan-2024 Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) AccessWire
04-Jan-2024 Single Cell RNA Sequencing Kits Market: Trends, Innovations, and Growth Opportunities Stringent Datalytics
04-Jan-2024 Gerresheimer AG: Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy  Gerresheimer AG
04-Jan-2024 Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece AccessWire
04-Jan-2024 NanoViricides to Present at the Biotech Showcase in San Fransisco AccessWire
04-Jan-2024 TRYP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2a CLINICAL TRIAL FOR THE TREATMENT OF FIBROMYALGIA AT THE UNIVERSITY OF MICHIGAN Tryp Therapeutics Inc.
04-Jan-2024 Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan AccessWire
04-Jan-2024 Abivax 2024 Financial Communication Calendar ABIVAX
04-Jan-2024 Angle PLC Announces Breakthrough Clinical Results AccessWire
04-Jan-2024 Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I Evotec SE
04-Jan-2024 Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA AccessWire
04-Jan-2024 Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals S.p.A.
04-Jan-2024 Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA Kuros Biosciences AG